Innovation Pipeline Services About Us News & Media Careers Governance Investors

Innovation
Pipeline
Services
About Us
News & Media
Careers
Governance
Investors
Contact

Home
News & Media
Press Releases
Philogen Receives Orphan Drug Designation for the Treatment of Melanoma

Press Release

Published: July 18, 2018

Philogen Receives Orphan Drug Designation for the Treatment of Melanoma

PRESS RELEASE DAROMUN

Company

Innovation
Pipeline
Services
About Us
News & Media
Careers
Governance
Investors

Connect

Contact
LinkedIn
X
Philochem

Legal

Privacy Policy
Cookie Policy
POR-CREO project notice

Registered officePiazza La Lizza, 7 — 53100 Siena (SI), Italy
Headquarters & Rosia GMP FacilityVia Bellaria, 35 — 53018 Sovicille (SI), Italy
Montarioso GMP FacilityVia Montarioso, 11 — 53035 Monteriggioni (SI), Italy
Clinical OperationsVia Privata Maria Teresa, 7 — 20123 Milano (MI), Italy
Philochem AG (Discovery Unit — subsidiary)Libernstrasse 3 — CH-8112 Otelfingen, Switzerland

© 2026 Philogen S.p.A.REA SI-98772 · P.IVA e CF 00893990523 · Cap. Soc. € 5.731.226,64 i.v.